Mirae Asset Global Etfs Holdings Ltd. Zentalis Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.9 Billion
- Q4 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 32,714 shares of ZNTL stock, worth $58,558. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,714
Previous 31,262
4.64%
Holding current value
$58,558
Previous $114,000
13.16%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ZNTL
# of Institutions
147Shares Held
65.3MCall Options Held
43.2KPut Options Held
21.7K-
Matrix Capital Management Company, LP Waltham, MA14MShares$25 Million2.05% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$8.63 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.48MShares$8.01 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$5.86 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.22MShares$5.76 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $102M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...